MCTT

MCTT (Medical Cell Technology & Tissue), now operating as Biosolution, is a South Korean biotechnology company at the forefront of regenerative medicine and cell therapy. Founded in 2000, the company specializes in tissue engineering and the development of cell-based products for skin and cartilage repair. Its commercial portfolio includes KeraHeal, an autologous keratinocyte therapy for severe burns, and CartiLife, an autologous chondrocyte treatment for cartilage defects. MCTT's technology platform focuses on high-purity cell isolation and large-scale cultivation to address unmet needs in dermatology and orthopedics. The company also provides 3D human skin models, such as KeraSkin, for in vitro toxicity testing and dermatological research.